• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Mirum Pharma to Showcase Livmarli & Volixibat Data at AASLD

    BUSINESSWIRE

    Mirum Pharma Reports Q3 2024 Financial Results & Business Update

    BUSINESSWIRE

    Mirum Pharma Reports Inducement Grants Under Nasdaq LR 5635(c)(4)

    BUSINESSWIRE

    Mirum Pharma to Participate in Upcoming Investor Conferences

    BUSINESSWIRE

    Mirum Pharmaceuticals to Announce Q3 2024 Results on Nov 12

    BUSINESSWIRE

    Mirum Pharma Reports Inducement Grants Under Nasdaq LR 5635(c)(4)

    BUSINESSWIRE

    Volixibat Gets Breakthrough Status For Cholestatic Pruritus In PBC

    BUSINESSWIRE

    Abacus & Mirum Partner To Commercialize LIVMARLI In Nordic

    CONTRACT PHARMA

    Mirum Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)

    BUSINESSWIRE

    Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

    BUSINESSWIRE

    Mirum Pharmaceuticals Reports Inducement Grants

    BUSINESSWIRE

    Mirum Pharmaceuticals Reports Q2 2024 Results And Business Update

    BUSINESSWIRE

    Mirum Pharmaceuticals To Report Q2 2024 Results On August 7

    BUSINESSWIRE

    Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older

    BUSINESSWIRE

    Mirum Pharma Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)

    BUSINESSWIRE

    EU Approves Mirum`s LIVMARLI For PFIC Patients

    BUSINESSWIRE

    Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX

    BUSINESSWIRE

    Mirum’s Volixibat Achieves Positive Interim Analyses In VANTAGE PBC

    BUSINESSWIRE

    Mirum To Host Call On Volixibat VANTAGE VISTAS Interim Analysis

    BUSINESSWIRE

    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Rules

    BUSINESSWIRE

    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule

    BUSINESSWIRE

    Mirum`s LIVMARLI ALGS, PFIC Long-Term Data At EASL

    BUSINESSWIRE

    Mirum`s LIVMARLI Long-Term ALGS, PFIC Data At EASL

    BUSINESSWIRE

    Mirum Pharma: Presenting At Goldman Sachs Healthcare Event

    BUSINESSWIRE

    Mirum Pharma announces positive CHMP opinion for Livmarli oral solution

    PHARMABIZ

    Mirum`s LIVMARLI Gets Positive CHMP Opinion For PFIC From 3 Months

    BUSINESSWIRE

    Mirum`s LIVMARLI Long-Term ALGS/PFIC Data At EASL Congress

    BUSINESSWIRE

    Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting

    BUSINESSWIRE

    Mirum Inducement Grants Under Nasdaq Rule

    BUSINESSWIRE

    Mirum Pharmaceuticals: Q1 2024 Financials, Business Update

    BUSINESSWIRE

    Mirum LIVMARLI PFIC Data Published In The Lancet

    BUSINESSWIRE

    Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference

    BUSINESSWIRE

    Mirum Q1 2024 Results, Conference Call On May 8

    BUSINESSWIRE

    Mirum Pharmaceuticals Reports Inducement Grants

    BUSINESSWIRE

    Mirum LIVMARLI Receives Positive Reimbursement Recommendation by Canada

    BUSINESSWIRE

    US FDA approves expanded use of Mirum`s liver disease drug

    REUTERS

    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    PRESS RELEASE

    Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

    BUSINESSWIRE

    Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI

    BUSINESSWIRE

    Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results

    BUSINESSWIRE

    Mirum Pharma to Announce Fourth Quarter and Year-End 2023 Financial Results

    BUSINESSWIRE

    Mirum Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BUSINESSWIRE

    Mirum Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BUSINESSWIRE

    Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer

    BUSINESSWIRE

    Mirum Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BUSINESSWIRE

    Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue

    BUSINESSWIRE

    Mirum Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

    BUSINESSWIRE

    Mirum Pharma Announces Data from EMBARK Phase 2b Study for Biliary Atresia

    BUSINESSWIRE

    Mirum Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BUSINESSWIRE

    Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference

    BUSINESSWIRE

    Mirum Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BUSINESSWIRE

    Mirum Pharmaceuticals Presents New Data at The Liver Meeting®

    BUSINESSWIRE

    Mirum Pharmaceuticals to Present at the 2023 UBS Biopharma Conference

    BUSINESSWIRE

    Mirum Reports Third Quarter 2023 Financial Results and Provides Business Update

    BUSINESSWIRE

    Mirum Pharmaceuticals to Present New Data at The Liver Meeting®

    BUSINESSWIRE

    Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results

    BUSINESSWIRE

    Mirum Pharmaceuticals Announces New PDUFA Date for LIVMARLI

    BUSINESSWIRE

    Mirum Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BUSINESSWIRE

    Mirum Presents LIVMARLI Clinical Data and Real-World Evidence at NASPGHAN

    BUSINESSWIRE

    Mirum Announces Positive Phase 3 RESTORE Study Results Evaluating Chenodal

    BUSINESSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.